Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Chemistry - A European Journal Année : 2017

Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines

Résumé

The large majority of TACA-based (TACA=Tumor-Associated Carbohydrate Antigens) antitumor vaccines target only one carbohydrate antigen, thereby often resulting in the incomplete destruction of cancer cells. However, the morphological heterogeneity of the tumor glycocalix, which is in constant evolution during malignant transformation, is a crucial point to consider in the design of vaccine candidates. In this paper, an efficient synthetic strategy based on orthogonal chemoselective ligations to prepare fully synthetic glycosylated cyclopeptide scaffolds grafted with both Tn and TF antigen analogues is reported. To evaluate their ability to be recognized as tumor antigens, direct interaction ELISA assays have been performed with the anti-Tn monoclonal antibody 9A7. Although both heterovalent structures showed binding capacities with 9A7, the presence of the second TF epitope did not interfere with the recognition of Tn except in one epitope arrangement. This heterovalent glycosylated structure thus represents an attractive epitope carrier to be further functionalized with T-cell peptide epitopes.
Fichier principal
Vignette du fichier
Pifferi_et_al-2017-Chemistry_-_A_European_Journal.pdf (2.83 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03323891 , version 1 (23-08-2021)

Identifiants

Citer

Carlo Pifferi, Baptiste Thomas, David Goyard, Nathalie Berthet, Olivier Renaudet. Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines. Chemistry - A European Journal, 2017, 23 (64), pp.16283-16296. ⟨10.1002/chem.201702708⟩. ⟨hal-03323891⟩
81 Consultations
28 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More